{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:19:35Z","timestamp":1791976775591,"version":"4.4.0"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T00:00:00Z","timestamp":1534377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0201836","type":"journal-article","created":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T13:34:35Z","timestamp":1534426475000},"page":"e0201836","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":129,"title":["High-sensitivity C-reactive protein in heart failure with preserved ejection fraction"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8410-4429","authenticated-orcid":true,"given":"Hilary M.","family":"DuBrock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar F.","family":"AbouEzzeddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret M.","family":"Redfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,8,16]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"WJ Paulus","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"11","key":"ref2","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrendo.2017.90","article-title":"Adapting to obesity with adipose tissue inflammation","volume":"13","author":"SM Reilly","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"ref3","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1172\/JCI200318921","article-title":"C-reactive protein: a critical update","volume":"111","author":"MB Pepys","year":"2003","journal-title":"J Clin Invest"},{"issue":"16","key":"ref4","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"GK Hansson","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection","volume":"118","author":"PM Ridker","year":"2016","journal-title":"Circ Res"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejheart.2007.11.003","article-title":"C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease","volume":"10","author":"ES Williams","year":"2008","journal-title":"Heart and Soul Study. Eur J Heart Fail"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cardfail.2005.08.003","article-title":"High-sensitivity C-reactive protein and parameters of left ventricular dysfunction","volume":"12","author":"SJ Shah","year":"2006","journal-title":"J Card Fail"},{"issue":"12","key":"ref8","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"PM Ridker","year":"2017","journal-title":"The New England journal of medicine"},{"key":"ref9","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","author":"PM Ridker","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"ref10","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/ejhf.104","article-title":"C-reactive protein predicts mortality in patients referred for coronary angiography and symptoms of heart failure with preserved ejection fraction","volume":"16","author":"L Koller","year":"2014","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.amjcard.2013.08.047","article-title":"Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)","volume":"113","author":"BW Van Tassell","year":"2014","journal-title":"The American journal of cardiology"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1161\/CIRCRESAHA.113.301141","article-title":"Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension","volume":"115","author":"M Rabinovitch","year":"2014","journal-title":"Circ Res"},{"issue":"14","key":"ref13","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.jacc.2008.12.038","article-title":"C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension","volume":"53","author":"R Quarck","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"issue":"25","key":"ref14","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1161\/CIRCULATIONAHA.114.013536","article-title":"It is time to look at heart failure with preserved ejection fraction from the right side","volume":"130","author":"NA Chatterjee","year":"2014","journal-title":"Circulation"},{"issue":"25","key":"ref15","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1161\/CIRCULATIONAHA.113.008461","article-title":"Right ventricular function in heart failure with preserved ejection fraction: a community-based study","volume":"130","author":"SF Mohammed","year":"2014","journal-title":"Circulation"},{"issue":"17","key":"ref16","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1161\/CIRCULATIONAHA.117.031608","article-title":"Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction","volume":"137","author":"AU Fayyaz","year":"2018","journal-title":"Circulation"},{"issue":"12","key":"ref17","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"MM Redfield","year":"2013","journal-title":"JAMA"},{"issue":"5","key":"ref18","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1161\/CIRCHEARTFAILURE.112.969071","article-title":"PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design","volume":"5","author":"MM Redfield","year":"2012","journal-title":"Circ Heart Fail"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","article-title":"Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology","volume":"18","author":"RM Lang","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1161\/CIRCHEARTFAILURE.113.000568","article-title":"Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study","volume":"7","author":"R Zakeri","year":"2014","journal-title":"Circ Heart Fail"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/01.CIR.0000052939.59093.45","article-title":"Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association","volume":"107","author":"TA Pearson","year":"2003","journal-title":"Circulation"},{"issue":"19","key":"ref22","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2009.12.045","article-title":"Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study","volume":"55","author":"A Kalogeropoulos","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"issue":"22","key":"ref23","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1161\/CIRCULATIONAHA.109.849117","article-title":"Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis","volume":"120","author":"JJ McMurray","year":"2009","journal-title":"Circulation"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004382","article-title":"Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction","volume":"6","author":"OF AbouEzzeddine","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"ref25","first-page":"245","article-title":"Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure)","volume":"3","author":"OF AbouEzzeddine","year":"2015","journal-title":"JACC Heart failure"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamacardio.2016.4726","article-title":"Factors Associated With and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure With Preserved Ejection Fraction: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program","volume":"2","author":"A Pandey","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"5","key":"ref27","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/CIRCHEARTFAILURE.111.962654","article-title":"Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial","volume":"4","author":"IS Anand","year":"2011","journal-title":"Circulation Heart failure"},{"issue":"14","key":"ref28","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jacc.2012.12.044","article-title":"B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction","volume":"61","author":"DJ van Veldhuisen","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"10","key":"ref29","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1161\/CIRCULATIONAHA.104.508465","article-title":"C-reactive protein in heart failure: prognostic value and the effect of valsartan","volume":"112","author":"IS Anand","year":"2005","journal-title":"Circulation"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijcard.2016.11.110","article-title":"Biomarkers for characterization of heart failure\u2014Distinction of heart failure with preserved and reduced ejection fraction","volume":"227","author":"C Sinning","year":"2017","journal-title":"Int J Cardiol"},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"e0157159","DOI":"10.1371\/journal.pone.0157159","article-title":"Multi-Marker Strategy in Heart Failure: Combination of ST2 and CRP Predicts Poor Outcome","volume":"11","author":"AM Dupuy","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/CIRCHEARTFAILURE.109.931451","article-title":"Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction","volume":"4","author":"D Westermann","year":"2011","journal-title":"Circ Heart Fail"},{"issue":"24","key":"ref33","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1161\/01.CIR.0000103131.70301.4F","article-title":"Inflammation as a risk factor for atrial fibrillation","volume":"108","author":"RJ Aviles","year":"2003","journal-title":"Circulation"},{"issue":"3","key":"ref34","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1164\/rccm.200605-713OC","article-title":"C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease","volume":"175","author":"M Dahl","year":"2007","journal-title":"American journal of respiratory and critical care medicine"},{"issue":"2","key":"ref35","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1161\/01.CIR.85.2.504","article-title":"Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure","volume":"85","author":"RJ Cody","year":"1992","journal-title":"Circulation"},{"issue":"24","key":"ref36","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"A Giaid","year":"1993","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"ref37","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/eurheartj\/ehi631","article-title":"NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study","volume":"27","author":"JL Januzzi","year":"2006","journal-title":"Eur Heart J"},{"issue":"5","key":"ref38","doi-asserted-by":"crossref","DOI":"10.4172\/2161-105X.1000295","article-title":"Circulating Aldosterone Levels and Disease Severity in Pulmonary Arterial Hypertension","volume":"5","author":"Z Safdar","year":"2015","journal-title":"J Pulm Respir Med"},{"issue":"4","key":"ref39","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ahj.2004.07.010","article-title":"Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy","volume":"149","author":"DG Krauser","year":"2005","journal-title":"Am Heart J"},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.amjcard.2015.10.020","article-title":"Usefulness of C-Reactive Protein Plasma Levels to Predict Exercise Intolerance in Patients With Chronic Systolic Heart Failure","volume":"117","author":"JM Canada","year":"2016","journal-title":"Am J Cardiol"},{"issue":"6","key":"ref41","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ahj.2007.03.044","article-title":"Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure","volume":"153","author":"JD Windram","year":"2007","journal-title":"Am Heart J"},{"issue":"4","key":"ref42","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1016\/j.ijcard.2013.06.028","article-title":"Relationship of CRP, IL-6, and fibrinogen with right ventricular structure and function: the MESA-Right Ventricle Study","volume":"168","author":"MO Harhay","year":"2013","journal-title":"International journal of cardiology"},{"issue":"6","key":"ref43","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1183\/09031936.00016006","article-title":"NT-proBNP reflects right ventricular structure and function in pulmonary hypertension","volume":"28","author":"CT Gan","year":"2006","journal-title":"The European respiratory journal"},{"issue":"5","key":"ref44","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1378\/chest.129.5.1313","article-title":"Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension","volume":"129","author":"A Fijalkowska","year":"2006","journal-title":"Chest"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0201836","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T07:53:04Z","timestamp":1571730784000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0201836"}},"subtitle":[],"editor":[{"given":"Yoshihiro","family":"Fukumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,8,16]]},"references-count":44,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0201836","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,16]]}}}